| Literature DB >> 24790988 |
Vanessa Bley Ribeiro1, Adriano Rostirolla Linhares2, Alexandre P Zavascki3, Afonso Luis Barth1.
Abstract
Modified Hodge Test (MHT) has been suggested as screening tests for carbapenemases, but concerns regarding its difficult interpretation and common false-positive results obtained in the presence of other β -lactamases have been noted. This study aimed to quantify the enhanced growth formed by the indicator strain and thus evaluate the performance of a quantitative interpretation of MHT for KPC screening. MHT was performed in 50 KPC-producing isolates and 334 non-carbapenemase-producing isolates, using ertapenem (ETP) and meropenem (MEM) as substrates. The size of enhanced growth of indicator strain was measured for each isolate tested and for the positive control used, and a ratio was calculated. Our results revealed 17 different ETP and MEM ratios, with distinct sensitivity (SN) and specificity (SP). Higher SN combined to higher SP was achieved when ETP and MEM ratios were 0.45, with a SN value of 96% for both substrates and SP values of 99.4% and 100% for ETP and MEM, respectively. The quantification with both substrates increased SP of the test for KPC detection. Considering that MHT is the unique phenotypic test that is referred to by CLSI, a more accurate approach for its interpretation could be applied to make it a more useful tool.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24790988 PMCID: PMC3984814 DOI: 10.1155/2014/139305
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Minimal inhibitory concentration (MIC) of carbapenems of the 384 isolates evaluated.
| Isolates |
| MIC (mg/L)a | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imipenem | Meropenem | Ertapenem | |||||||||||
| MICb | MIC50 | MIC90 | Range | MICb | MIC50 | MIC90 | Range | MICb | MIC50 | MIC90 | Range | ||
| KPC-producing isolates | 50 | — | 16 | 128 | 1.0–256 | — | 32 | 128 | 4.0–>256 | — | 64 | 256 | 4.0–>256 |
|
| 36 | — | 16 | 64 | — | 32 | 64 | — | 64 | 128 | |||
|
| 10 | — | 8 | 64 | — | 16 | 128 | — | 32 | 256 | |||
|
| 3 | — | 128 | 256 | — | 32 | 64 | — | 64 | 128 | |||
|
| 1 | 256 | — | — | 128 | — | — | 128 | — | — | |||
| Non-carbapenemase-producing isolates | 334 | — | 0.5 | 2.0 | ≤0.5–32 | 0.5 | 4.0 | ≤0.5–32 | 4.0 | 16 | ≤0.5–128 | ||
|
| 220 | — | 0.5 | 2.0 | 0.5 | 2.0 | 4.0 | 8.0 | |||||
|
| 89 | — | 1.0 | 4.0 | 1.0 | 8 | 4.0 | 32 | |||||
|
| 17 | — | 0.5 | 4.0 | 1.0 | 4.0 | 4.0 | 16 | |||||
|
| 5 | — | 1.0 | 4.0 | 1.0 | 4.0 | 2.0 | 8.0 | |||||
|
| 1 | 2.0 | — | — | 0.5 | — | — | 0.5 | — | — | |||
|
| 1 | 4.0 | — | — | 0.5 | — | — | 0.5 | — | — | |||
|
| 1 | ≤0.5 | — | — | 0.5 | — | — | 0.5 | — | — | |||
aDetermined by broth microdilution [17].
bResult of MIC of species with a single isolate.
Figure 1Quantification of Modified Hodge Test (MHT). The enhanced growth ratio of ETP and MEM subtracts were obtained from the measure (mm) of the enhanced growth of E. coli ATCC 25922 for both the isolate and the KPC-producing positive control (K. pneumoniae ATCC BAA 1705) and a ratio was calculated. In this example, B is the positive control and the enhanced growth measured for ETP was 10 mm. The enhanced growth measured for isolates A and C was 5 and 2 mm, respectively, resulting in ETP enhanced ratios of 0.5 and 0.2, respectively.
Sensitivity (SN) and specificity (SP) of distinct values of ertapenem (ETP) enhanced growth ratios.
| ETP ratios | SN (%) | SP (%) |
|---|---|---|
| 0.045 | 100.0 | 28.4 |
| 0.095 | 100.0 | 29.3 |
| 0.106 | 100.0 | 63.5 |
| 0.118 | 100.0 | 64.1 |
| 0.134 | 100.0 | 65.6 |
| 0.171 | 100.0 | 67.1 |
| 0.211 | 96.0 | 90.7 |
| 0.254 | 96.0 | 91.3 |
| 0.293 | 96.0 | 92.5 |
| 0.317 | 96.0 | 97.0 |
| 0.367 | 96.0 | 97.3 |
| 0.450 | 96.0 | 99.4 |
| 0.583 | 94.0 | 99.7 |
| 0.683 | 92.0 | 99.7 |
| 0.750 | 82.0 | 99.7 |
| 0.850 | 70.0 | 99.7 |
| 0.950 | 58.0 | 99.7 |
Sensitivity (SN) and specificity (SP) of distinct values of meropenem (MEM) enhanced growth ratios.
| MEM ratios | SN (%) | SP (%) |
|---|---|---|
| 0.045 | 100.0 | 28.4 |
| 0.095 | 100.0 | 29.3 |
| 0.113 | 100.0 | 79.0 |
| 0.134 | 100.0 | 79.9 |
| 0.162 | 100.0 | 81.7 |
| 0.191 | 100.0 | 82.3 |
| 0.225 | 98.0 | 94.6 |
| 0.268 | 98.0 | 95.2 |
| 0.293 | 98.0 | 95.8 |
| 0.350 | 96.0 | 98.5 |
| 0.450 | 96.0 | 100.0 |
| 0.550 | 94.0 | 100.0 |
| 0.560 | 90.0 | 100.0 |
| 0.750 | 86.0 | 100.0 |
| 0.838 | 66.0 | 100.0 |
| 0.888 | 62.0 | 100.0 |
| 0.950 | 54.0 | 100.0 |
Positive predictive values (PPV) and negative predictive values (NPV) of the quantitative Modified Hodge Test, according to estimated population prevalence of bla KPC-2.
|
Population prevalence of | MEM | ERT | ||
|---|---|---|---|---|
| PPV (95% CI) | NPV (95% CI) | PPV (95% CI) | NPV (95% CI) | |
| 10% | 97.3% (87.8–99.4%) | 99.6% (98.5–99.9%) | 94.7% (83.8–98.4%) | 99.6% (98.5–99.9%) |
| 20% | 98.8% (94.2–99.8%) | 99.0% (96.7–99.7%) | 97.6% (92.1–99.3%) | 99.0% (96.7–99.7%) |
| 30% | 99.3% (96.5–99.9%) | 98.3% (94.5–99.5%) | 98.6% (95.2–99.6%) | 98.3% (94.5–99.5%) |
| 50% | 99.7% (98.0–99.9%) | 96.1% (88.0–98.8%) | 99.4% (97.9–99.8%) | 96.1% (88.0–98.3%) |
| 70% | 99.9% (99.3–100%) | 91.4% (75.9–97.3%) | 99.7% (99.1–99.9%) | 91.4% (75.9–97.3%) |
MEM: meropenem; ERT: ertapenem.
Figure 2Ertapenem enhanced growth ratio (ER) ROC curve (a) and meropenem enhanced growth ratio (MR) ROC curve (b). AUC = area under the curve; CI = confidence interval.